In vitro antileishmanial properties of neutron-irradiated meglumine antimoniate

Brazilian Archives of Biology and Technology

Volumn 48, Issue SPECIL ISS. 2, 2005, Pages 63-68

  Borborema, Samanta Etel Treiger ^a   Junior, Heitor Franco de Andrade ^b   Junior, João Alberto Osso ^a   do Nascimento, Nanci ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Leishmania (L.) Chagasi; Leishmaniasis; Meglumine antimoniate; Radiotracer

Indexed keywords

EID: 78650270672     PISSN: 15168913     EISSN: 16784324     Source Type: Journal    
DOI: 10.1590/S1516-89132005000700009     Document Type: Article

References (11)

1. Croft, S. L. and Coombs, G. H. (2003), Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitology, 19, 502-508.
2. Guerin, P. J.; Olliaro, P.; Sundar, S.; Boelaert, M.; Croft, S. L.; Desjeux, P.; Wasunna, M. K. and Bryceson, A. D. (2002), Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. The Lancet Infectious Diseases, 2, 494-501.
3. Meikle S. R.; Eberl S. and Iida, H. (2001), Instrumentation and methodology for quantitative pre-clinical imaging studies. Current Pharmaceutical Design, 7, 1945-66.
4. Murray H. W. (2001), Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 45, 2185-2197.
5. Rath, S.; Trivelin, L. A.; Imbrunito, T. R.; Tomazela, D. M.; Jesus, M. M.; Marzal, P. C.; Andrade Jr., H. F. and Tempone, A. G. (2003), Antimoniais empregados no tratamento da leishmaniose: estado da arte. Quimica. Nova, 26, 550-555.
6. Roberts, W.; Mcmurray, W. J. and Rainey, P. M. (1998), Characterization of the antimonial antileishmanial agent meglumine antimoniate (glucantime). Antimicrobial Agents and Chemotherapy, 42, 1076-1082.
7. Romero, G. A. S.; Oliveira, M. R. F.; Dalmo, C. and Marsden, P. D. (1996), Características físico-químicas do antimoniato de meglumina em diferentes condições de armazenamento. Revista da Sociedade Brasileira de Medicina Tropical, 29, 461-465.
8. Shaked-Mishan, P.; Ulrich, N.; Ephros, M. and Zilberstein, D. (2001), Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. The Journal of Biological Chemistry, 276, 3971-3976.
9. Singh, S. and Sivakumar, R. (2004), Challenges and new discoveries in the treatment of leishmaniasis. Journal of Infection and Chemotherapy, 10, 307-315.
10. Tempone, A. G..; Borborema, S. E. T.; Andrade Jr., H. F.; Gualda, N. C. A.; Yogi, A.; Carvalho, C. S.; Bachiega, D.; Lupo, F. N.; Bonoto, S. V. and Fischer, D. C. H. (2005), Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloid-producing families. Phytomedicine, 12, 382-390.
11. Yan, S.; Li, F.; Ding, K. And Sun, H. (2003), Reduction of pentavalent antimony by tripanothione and formation of a binary and ternary complex of antimony (III) and trypanothione. Journal of Biological and Inorganic Chemistry, 8, 689-697.